Ginkgo biloba and Cashew Applications
Ginkgo biloba, one of the oldest living tree species, has been used medicinally for centuries, and modern research is now working to understand precisely how its active compounds — particularly the terpene trilactones and flavonoid glycosides found in standardized leaf extracts — exert their effects on the brain. Much of the current scientific interest centers on whether these compounds can slow or prevent the neuronal damage associated with Alzheimer's disease and other forms of dementia, likely through antioxidant mechanisms and modulation of cell-signaling pathways that protect neurons under stress. Researchers are also examining the pharmacokinetics of Ginkgo extracts to determine how well these molecules are absorbed, distributed, and metabolized in the human body — information that is essential before clinical benefits can be reliably established. Key open questions include whether regular supplementation meaningfully reduces cognitive decline in aging populations, and how findings might extend to related plant-derived compounds such as those from cashew, which shares some biochemically active constituents of emerging interest.
- Works
- 25,361
- Total citations
- 233,268
- Keywords
- Ginkgo BilobaNeuroprotectiveDementiaAntioxidantCognitive ImpairmentAlzheimer's Disease
Top papers in Ginkgo biloba and Cashew Applications
Ordered by total citation count.
- Association of single nucleotide polymorphisms in the lens epithelium-derived growth factor (LEDGF/p75) with HIV-1 infection outcomes in brazilian HIV-1+ individuals↗ 7,139OA
- Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study↗ 4,354OA
- Clinical diagnostic criteria for dementia associated with Parkinson's disease↗ 3,053
- Antioxidant Activity and Phenolic Compounds in Selected Herbs↗ 2,879
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines↗ 2,551OA
- Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases↗ 2,542OA
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030↗ 2,477
- The Parkinson Progression Marker Initiative (PPMI)↗ 1,944OA
- Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment↗ 1,860OA
- The Hawthorne Effect: a randomised, controlled trial↗ 1,733OA
- Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease↗ 1,562OA
- EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers↗ 1,435
Active researchers
Top authors in this area, ranked by h-index.